Friday, July 10, 2026

pharma · Syphilis · Human Immunodeficiency Virus

MEDA Pharma GmbH

MEDA Pharma GmbH is a pharma organization headquartered in CN. Primary therapeutic focus areas include Syphilis, Human Immunodeficiency Virus, Non Alcoholic Fatty Liver Disease, Human immunodeficency virus, COVID-10 infe

Bad Homburg, DE HQ
89 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Bad Homburg, DE
Employees
89
Programs
8
Drugs
28
Patents
0
Clinical program

BENZATHINE BENZYLPENICILLIN , LINEZOLID

Approved · small molecule · Syphilis

BENZATHINE BENZYLPENICILLIN , LINEZOLID for Syphilis is a Approved program (small_molecule) at MEDA Pharma GmbH & Co. KG with 1 ClinicalTrials.gov record(s).

← All MEDA Pharma GmbH & Co. KG projects Approved small molecule active

Internal code Trep-AB

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
MEDA Pharma GmbH & Co. KG
Phase
Approved
Modality
small_molecule
Indication
Syphilis
Status
active
Trials
1